Search Results - "Sengelov, L"

Age-related Differences in Recall of Information and Handling of Chemotherapy-related Side Effects in Cancer Patients: The ReCap Study by Lund, Cecilia Margareta, Mikkelsen, M K, Theile, S, Michelsen, H M, Schultz, M, Sengeløv, L, Nielsen, D L

“…To prevent severe toxicity and hospital admissions, adequate management and recall of information about side effects are crucial and health literacy plays an…”
Get full text

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer by DROR MICHAELSON, M, OUDARD, Stephane, LAESTADIUS, Fredrik, ULLEN, Anders, BAHL, Amit, CASTELLANO, Daniel, GSCHWEND, Juergen, MAURINA, Tristan, CHOW MANEVAL, Edna, WANG, Shaw-Ling, LECHUGA, Maria Jose, PAOLINI, Jolanda, OU, Yen-Chuan, ISAN CHEN, SENGELØV, Lisa, SAAD, Fred, HOUEDE, Nadine, OSTLER, Peter, STENZL, Arnulf, DAUGAARD, Gedske, JONES, Robert

“…We evaluated angiogenesis-targeted sunitinib therapy in a randomized, double-blind trial of metastatic castration-resistant prostate cancer (mCRPC). Men with…”
Get full text

7105 POSTER DISCUSSION Belinostat in Combination With Carboplatin and Paclitaxel (BelCaP) for Treatment of Bladder Cancer – A Pharmacokinetic Study of Exposure to Belinostat and Its Metabolites by Jones, R.J, Tjornelund, J, Erichsen, K.D, Sengelov, L, De Bono, J

Get full text

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy by Fizazi, K., Ulys, A., Sengeløv, L., Moe, M., Ladoire, S., Thiery-Vuillemin, A., Flechon, A., Guida, A., Bellmunt, J., Climent, M.A., Chowdhury, S., Dumez, H., Matouskova, M., Penel, N., Liutkauskiene, S., Stachurski, L., Sternberg, C.N., Baton, F., Germann, N., Daugaard, G.

“…This phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer…”
Get full text

Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer by Roberts, J.T., von der Maase, H., Sengeløv, L., Conte, P.F., Dogliotti, L., Oliver, T., Moore, M.J., Zimmermann, A., Arning, M.

“…Purpose: To compare long-term survival in patients with locally advanced and metastatic transitional cell carcinoma (TCC) of the urothelium treated with…”
Get full text

Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer by SENGELØV, Lisa, KAMBY, Claus, GEERTSEN, Poul, ANDERSEN, Lisbeth Juhler, VON DER MAASE, Hans

“…To identify pretreatment variables predicting overall and complete response to cisplatin-based chemotherapy for metastatic urothelial cancer, and to study the…”
Get full text

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial by Kwon, Eugene D, Prof, Drake, Charles G, MD, Scher, Howard I, Prof, Fizazi, Karim, Prof, Bossi, Alberto, MD, van den Eertwegh, Alfons J M, MD, Krainer, Michael, MD, Houede, Nadine, MD, Santos, Ricardo, MD, Mahammedi, Hakim, MD, Ng, Siobhan, MD, Maio, Michele, MD, Franke, Fabio A, MD, Sundar, Santhanam, MBBS, Agarwal, Neeraj, MD, Bergman, Andries M, MD, Ciuleanu, Tudor E, Prof, Korbenfeld, Ernesto, MD, Sengeløv, Lisa, MD, Hansen, Steinbjorn, MD, Logothetis, Christopher, Prof, Beer, Tomasz M, Prof, McHenry, M Brent, PhD, Gagnier, Paul, MD, Liu, David, MD, Gerritsen, Winald R, Prof

“…Summary Background Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. Our aim was to…”
Get full text

Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer by VON DER MAASE, Hans, SENGELOV, Lisa, ROBERTS, James T, RICCI, Sergio, DOGLIOTTI, Luigi, OLIVER, T, MOORE, Malcolm J, ZIMMERMANN, Annamaria, ARNING, Michael

“…To compare long-term survival in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium treated with…”
Get full text

Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data by Vale, C.L.

“…To update a systematic review and meta-analysis that assesses the effect of neoadjuvant chemotherapy in the treatment of patients with invasive bladder cancer…”
Get full text

Treatment outcome following radiotherapy in elderly patients with bladder cancer by Sengeløv, Lisa, Klintorp, Søren, Havsteen, Hanne, Kamby, Claus, Hansen, Susanne L., von der Maase, Hans

“…Background and purpose: The optimal treatment of elderly patients with bladder cancer is not established. This study aimed to evaluate prognostic variables for…”
Get full text

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of invasive bladder cancer by Sengeløv, L

Get full text

Adjuvant Chemotherapy in Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data by Vale, Claire L.

“…To evaluate the effect of adjuvant chemotherapy in invasive bladder cancer. We conducted a systematic review and meta-analysis of updated individual patient…”
Get full text

Assessment of patients with metastatic transitional cell carcinoma of the urinary tract by Sengeløv, L, von der Maase, H, Kamby, C, Jensen, L I, Rasmussen, F, Horn, T, Nielsen, S L, Steven, K

“…We propose an appropriate assessment of patients with disseminated transitional cell carcinoma of the urothelial tract, and investigate the pattern of…”
Get more information

Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer : A prospective study with more than 10 years of follow up by KAMBY, C, SENGELØV, L

“…The study evaluated prognostic factors for dissemination and survival in patients with local or regional recurrence of breast cancer. Furthermore, the aim was…”
Get full text

A Phase 2 Study with Epirubicin as Second-Line Treatment of Patients with Advanced Epithelial Ovarian Cancer by Havsteen, Hanne, Bertelsen, Kamma, Gadeberg, Carl C., Jacobsen, Anders, Kamby, Claus, Sandberg, Erik, Sengeløv, Lisa

“…Thirty-six patients with advanced epithelial ovarian cancer received epirubicin as second-line therapy after primary treatment with carboplatin and…”
Get full text

Radiotherapy in bladder cancer by Sengeløv, Lisa, von der Maase, Hans

“…In the present review, we have evaluated the outcome of radiotherapy in patients with bladder cancer. The exact value of radical radiotherapy is difficult to…”
Get full text

Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma by Hoyer, Morten, Roed, Henrik, Sengelov, Lisa, Traberg, Anders, Ohlhuis, Lars, Pedersen, Jorgen, Nellemann, Hanne, Kiil Berthelsen, Anne, Eberholst, Frey, Engelholm, Svend Aage, von der Maase, Hans

“…The majority of patients with pancreatic cancer have advanced disease at the time of diagnosis and are not amenable for surgery. Stereotactic radiotherapy…”
Get full text

Platinum analogue combination chemotherapy: cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors by Sengeløv, L, Nielsen, O S, Kamby, C, von der Maase, H

“…Cisplatin is one of the single drugs that has shown the best documented effect in treating patients with locally recurrent or metastatic urothelial cancer. To…”
Get more information

Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study by Sengeløv, L, Kamby, C, Lund, B, Engelholm, S A

“…Docetaxel and cisplatin has documented single-agent activity and different toxicity profiles in patients with metastatic urothelial cancer. We performed a…”
Get more information

106 Cabazitaxel adverse events are manageable in senior adults with metastatic castration-resistant prostate cancer (mCRPC): Results of the European Compassionate Use Programme by Heidenreich, A, Bracarda, S, Mason, M, Ozen, H, Sengelov, L, Gerritsen, W, Papandreou, C, Fossa, S, Hitier, S, Climent, M

Get full text